Scholarlink

<p>Technologies derived from the CRISPR (clustered regularly interspaced short palindromic repeats)–Cas immune system of prokaryotes have revolutionized our ability to cleave and modify target nucleic acid sequences. In addition to the use of CRISPR–Cas tools for the editing of human genes, they can also be designed to target pathogenic and commensal bacteria that colonize the body, offering new pathways for the treatment of infections and microbiome modulation. In this Review, we explore how the CRISPR–Cas toolbox can be engineered to kill or modify specific bacteria. We discuss DNA-targeting and RNA-targeting strategies, outlining how these can be applied to disarm bacteria by removing, modifying or silencing specific genes. Furthermore, we examine the delivery of CRISPR–Cas tools by bacteriophages and through conjugation and explore intracellular barriers to CRISPR–Cas tool maintenance and expression. Finally, we highlight therapeutic opportunities in the treatment of infectious diseases and for the modification of the microbiome, outlining progress and challenges in translating these approaches into clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CRISPR–Cas therapies targeting bacteria

  • 期刊论文

  • 发表日期：

    2025年5月13日

查看全文
  • Fabienne Benz,
  • Beatriz Beamud,
  • Raphael Laurenceau,
  • Amandine Maire,
  • Xavier Duportet,
  • Antoine Decrulle,
  • David Bikard

摘要

Technologies derived from the CRISPR (clustered regularly interspaced short palindromic repeats)–Cas immune system of prokaryotes have revolutionized our ability to cleave and modify target nucleic acid sequences. In addition to the use of CRISPR–Cas tools for the editing of human genes, they can also be designed to target pathogenic and commensal bacteria that colonize the body, offering new pathways for the treatment of infections and microbiome modulation. In this Review, we explore how the CRISPR–Cas toolbox can be engineered to kill or modify specific bacteria. We discuss DNA-targeting and RNA-targeting strategies, outlining how these can be applied to disarm bacteria by removing, modifying or silencing specific genes. Furthermore, we examine the delivery of CRISPR–Cas tools by bacteriophages and through conjugation and explore intracellular barriers to CRISPR–Cas tool maintenance and expression. Finally, we highlight therapeutic opportunities in the treatment of infectious diseases and for the modification of the microbiome, outlining progress and challenges in translating these approaches into clinical applications.